by Eric Christianson | Jul 31, 2022 | Hematology and Immunology Medication and Disease State Clinical Pearls
Sulfasalazine is classified as a DMARD (Disease-modifying antirheumatic drug) as well as a 5-aminosalicylic acid derivative. The most common use in clinical practice that I’ve seen sulfasalazine used for is rheumatoid arthritis, but it can also play a role in...
by Eric Christianson | Jul 20, 2022 | Neurology, Pain, and Musculoskeletal Medication and Disease State Clinical Pearls
Valproic acid is most commonly used for the management of seizures, bipolar disorder, and migraines. In my practice, I do see it occasionally used to help manage dementia-related aggressive behaviors. There are a lot of valproic acid clinical pearls that you need to...
by Eric Christianson | Jul 13, 2022 | Gastrointestinal Medication and Disease State Clinical Pearls
In part 2 of our series on CDAI basics in Crohn’s disease, I wanted to cover moderate to severe Crohn’s disease and how treatment may look a little different. As a quick refresher, CDAI stands for Crohn’s Disease Activity Index and as you can imagine...
by Eric Christianson | Jul 10, 2022 | Gastrointestinal Medication and Disease State Clinical Pearls
The Crohn’s Disease Activity Index (CDAI) is just what it sounds like. It is an assessment tool designed to determine the severity of Crohn’s disease. Wait, isn’t this a diagnostic tool intended for diagnosticians? As a pharmacist, why do I need to...
by Eric Christianson | Jul 3, 2022 | Endocrine Medication and Disease State Clinical Pearls
Systemic corticosteroids are an essential class of medication that is used to treat acute inflammation. One of the major indications that this class is used to treat is an acute asthma exacerbation. This is especially true in pediatric patients. In this article, I...
by Eric Christianson | Jun 8, 2022 | Medication and Disease State Clinical Pearls For Pharmacists, Psychiatry and Addiction Medication and Disease State Clinical Pearls
Long-Acting Injectable (LAI) Antipsychotics Antipsychotic agents are often discontinued without provider consultation, leading to poorer outcomes and quality of life. Luckily, newer formulations are continually being developed to help address barriers to care and...
